Supplier profile
Novo Nordisk Pharma GmbH
Every public-sector award we hold for this supplier, across Germany, from 22 Dec 2009 to 23 Sept 2026.
Awards won
16
all time
Attributed value
€6
5 shared, unvalued
Buyers
9
public bodies
Active
2009–2026
first to latest award
Awards by year
Who they win from
| Buyer | Awards | Value |
|---|---|---|
| AOK Baden-Württemberg | 4 | not attributable |
| AOK Sachsen - Anhalt | 2 | €2 |
| IKK classic | 2 | €2 |
| KKH-Allianz (Ersatzkasse) | 2 | not attributable |
| PBMG eG | 2 | not attributable |
| AOK Baden-Württemberg; handelnd im eigenen Namen und namens der unter VI.3 näher bezeichneten AOKs. | 1 | not attributable |
| AOK Bayern - Die Gesundheitskasse | 1 | not attributable |
| BKK Euregio | 1 | €1 |
| BKK24 | 1 | €1 |
What they win
Awards
All 16 awards we hold
- Germany – Pharmaceutical products – Arzneimittelrabattvereinbarung gemäß § 130a Abs. 8 SGB V zu dem Wirkstoff Concizumab (Alhemo®) ↗AOK Baden-Württembergshared awardawarded 23 Sept 2026
- Germany – Pharmaceutical products – Vereinbarung gemäß § 130c Abs. 1 SGB V über die Gewährung von Rabatten für patentgeschützte Arzneimittel mit den Wirkstoffen Turoctocog alfa (NovoEight®) und Turoctocog alfa pegol (Esperoct®). ↗AOK Baden-Württembergshared awardawarded 23 Sept 2026
- Germany – Pharmaceutical products – Arzneimittelrabattvertrag nach § 130a Abs. 8 SGB V i.V.m. § 130c Abs. 1 SGB V zu den Arzneimitteln Esperoct (B02BD02), NovoEight (B02BD02) und Alhemo (B02BX10) zur Behandlung der Hämophilie ↗AOK Sachsen - Anhalt€1awarded 3 Sept 2026
- Arzneimittelrabattvertrag nach § 130a Abs. 8 SGB V i.V.m. § 130c Abs. 1 SGB V zu den Arzneimitteln Esperoct (B02BD02), NovoEight (B02BD02) und Alhemo (B02BX10) zur Behandlung der Hämophilie ↗AOK Sachsen - Anhalt€1awarded 2 Sept 2026
- Ex-Ante-Transparenzbekanntmachung § 130a Abs. 8 SGB V i.V.m. § 130c Abs. 1 SGB V ATC-Code: B02BD16, ATC-Code: B02BD41; ATC-Code: B02BX10 ↗AOK Bayern - Die Gesundheitskasseawarded 23 Jul 2026
- Germany – Pharmaceutical products – Arzneimittelrabattvereinbarung gemäß § 130a Abs. 8 SGB V zu dem Wirkstoff Concizumab ↗AOK Baden-Württembergshared awardawarded 3 Feb 2026
- Germany – Pharmaceutical products – Abschluss eines nicht-exklusiven Rabattvertrages gemäß §§ 130a Abs. 8 und 130c Abs. 1 SGB V zwischen der IKK classic und der Novo Nordisk Pharma GmbH zu Alhemo ↗IKK classic€1awarded 28 Jan 2026
- Abschluss eines nicht-exklusiven Rabattvertrages gemäß §§ 130a Abs. 8 und 130c Abs. 1 SGB V zwischen der IKK classic und der Novo Nordisk Pharma GmbH zu Alhemo ↗IKK classic€1awarded 27 Jan 2026
- Germany – Pharmaceutical products – Arzneimittelvergaben zum 01.01.2026 und 01.07.2026 ↗PBMG eGawarded 5 Jan 2026
- Germany – Pharmaceutical products – Abschluss von nicht exklusiven Rabattverträgen gemäß § 130a Abs. 8 SGB V zu Arzneimitteln (Open-House-Verfahren) ↗AOK Baden-Württembergshared awardawarded 11 Mar 2025
- Germany – Pharmaceutical products – Arzneimittelvergaben zum 1.Juli 2024 ↗PBMG eGawarded 7 Jun 2024
- Germany-Heinsberg: Pharmaceutical products ↗BKK Euregio€1awarded 3 Feb 2023
- Germany-Obernkirchen: Pharmaceutical products ↗BKK24€1awarded 5 Sept 2018
- Somatropin. ↗KKH-Allianz (Ersatzkasse)awarded 9 Dec 2011
- Insulin Detemir. ↗KKH-Allianz (Ersatzkasse)awarded 2 Aug 2010
- Alfacalcidol. ↗AOK Baden-Württemberg; handelnd im eigenen Namen und namens der unter VI.3 näher bezeichneten AOKs.shared awardawarded 22 Dec 2009
Possibly the same organisation
These entries differ from this one only by legal form or a bracketed qualifier, so they may be the same organisation — or a different registered company of the same name. They are kept apart on purpose: the figures on each page are per legal entity and are never combined.
Bidding against them?
Get new tenders in their space in a daily digest, scored against your own capability — plus the full notice behind each of these awards, with the documents and contacts it published.
Start 7-day free trialHow this profile is built
Awards are collected from official public procurement notices and deduplicated so one procurement counts once. Supplier names are grouped across their published spellings: case and punctuation are ignored, and “Ltd” is treated as optional because buyers routinely leave it off. Everything else that marks a different organisation is kept — an LLP, a plc, a CIC and a Teoranta are separate businesses from a Ltd of the same name, as are a parent and a named subsidiary, and none of them are merged here. Where another entry differs from this one only by legal form or a bracketed qualifier it is listed above as possibly the same organisation — a hint for the reader, never a merge: figures are per legal entity and never combined. Value is attributed only where the notice is explicit: the supplier's own itemised amount, or the whole value where they were the sole named supplier. Awards naming several suppliers without a published split are counted and marked shared, never valued, and a framework ceiling is never treated as money any one appointed supplier won. Sterling and euro are never added together. The linked source notice is authoritative. Profiles may take up to an hour to reflect newly collected records.
Company pages are for organisations. If this page profiles you as an individual — a sole trader or an individual contractor — you can ask for it to be withheld: see how.